Merck agreed to a high-profile licensing deal for a KRAS G12D inhibitor, paying SciBrunch Therapeutics $400 million upfront for global rights to a preclinical candidate, with total deal value reaching $2.13 billion tied to milestones. The transaction adds another asset to the expanding KRAS G12D race as companies compete for differentiated biology, potency, and clinical differentiation. The deal also signals continued willingness by large pharma to fund early-stage, preclinical oncology bets with structured milestone economics. Clinical advancement and the eventual IND-enabling package will determine whether this preclinical inhibitor can translate into a defensible therapeutic profile.